Cellecta is a biotech company developing advanced high-throughput genetic screen technologies for the discovery and functional characterization of novel therapeutic targets and drugs.
Cellecta – functional screening and drug target discovery
Cellecta offers highly customized contract research services to develop advanced high-throughput RNAi and peptide technologies. Using lentiviral-based cloning and advanced library construction techniques, Cellecta has developed platforms for RNAi and CRISPR genome-wide genetic knockdown/ knockout screening and large-scale functional peptide screening. Indeed, the unique capabilities of lentiviral and shRNA technologies provide a platform that enables genome-wide functional screening. Thus, Cellecta offers researchers access to advanced RNAi screening services, pooled genome-wide shRNA libraries, individual lentiviral constructs, peptide screening, and related products and services. Cellecta also provides a service to quickly and effectively generate very high numbers of packaged, transduction-ready lentiviral plasmids. Furthermore, Cellecta offers lentiviral vector cloning services for the construction of custom cDNA expression plasmids and reporter constructs. Additionally, Cellecta provides a range of custom-designed cell lines for gene function analysis, compound screening assays, etc…
Cellecta was founded in 2006 and is headquartered in Mountain View (USA) in the heart of Silicon Valley. The company resides in the “Biotech Bay” area near some of the most well-known research biotech companies (Affymetrix, Genentech, etc…). Cellecta is headed by an experienced management and product development team with a good product development track record and a network of outside scientific collaborators. Cellecta is connected to a large network of collaborators and has partnered with a multitude of scientists and institutions (Fred Hutchinson Cancer Research Center (FHCRC), Roswell Park Cancer Institute, The Scripps Research Institute (TSRI), Harvard School of Public Health, etc…). Cellecta’s scientists have developed the most advanced technology available with funding from 12 NIH SBIR grants.
More about this biotech company : www.cellecta.com